Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Can France Stay in the Game?

This article was originally published in Start Up

Executive Summary

The French government's efforts to encourage biotechnology have been modest and somewhat piecemeal. Yet two years ago, France's industry was nevertheless ranked second in Europe. Since then, the explosion of biotech companies in Germany, along with steady growth in other European markets, make the need for a coherent French strategy more urgent. France needs to take some bolder, more generous measures--particularly to reduce companies' tax burden and attract talent from overseas--without which it risks restricting itself to a small group of companies, many of whom will have to move elsewhere to grow substantially.

You may also be interested in...



NicOx: Challenging the Cox-2s?

Recent concerns over the cardiovascular risk profile of Cox-2 inhibitors strengthen the case for pain compound AZD 3582, a new formulation of naproxen in Phase II trials at AstraZeneca. For the compound's originator, NicOx, forthcoming trial results will be critical in validating the firm's founding concept: grafting a nitric oxide molecule onto existing generic drugs.

Spotlight: France: What the President Must do for Biotech

Entrepreneur Philippe Pouletty, president of France Biotech, spells out to In Vivo Europe what's holding France's industry back, and what newly elected President Jacques Chirac needs to do about it.

BioXell: A New Beginning for Italian Biotech

The creation of Roche spin-off BioXell may signal a change in Italy's hitherto unfriendly biotech environment. Yet much remains to be done.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC090455

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel